Enlivex Therapeutics Ltd. (ENLV) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
71
First IPO Date
July 31, 2014
| Name | Title | Pay | Year Born |
| Oren Hershkovitz | Chief Executive Officer | 273,600 | 1977 |
| Shachar Shlosberger | Chief Financial Officer | 126,000 | 1977 |
| Dror Mevorach | Founder and Scientific Advisor | 180,000 | 1956 |
| Shai Novik | Executive Chairman | 528,000 | 1966 |
| Veronique Amor-Baroukh | Senior Director of Operations | 0 | N/A |
| Einat Galamidi | Chief Medical Officer | 0 | 1974 |
| Sigal Arad | Director of Human Resources | 0 | N/A |
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.